Stifel reiterates Glaukos stock rating on strong Epioxa survey
Stifel has reiterated its Buy rating and $190 price target for Glaukos Corporation following a positive survey regarding the company's Epioxa product. The survey indicated a significant fourfold increase in Epioxa procedures in Q3 2026, suggesting strong sales growth. Despite an InvestingPro analysis indicating the stock might be overvalued, Stifel maintains a positive outlook due to improved insurance coverage and the potential for multiple long-term winners in the cross-linking market.
Stifel reiterates Glaukos stock rating on strong Epioxa survey
Stifel reaffirmed its Buy rating and $190 price target for Glaukos Corporation (NYSE:GKOS) after a positive survey regarding its Epioxa product. The survey indicated a fourfold increase in Epioxa procedures in Q3 2026, suggesting strong sales growth. Analysts also highlighted Glaukos's impressive Q2 2026 revenue and strong performance of its iDose and Epioxa products.
Glaukos stock reports 49.60 percent Q2 revenue growth
Glaukos (GKOS) reported a 49.60% year-over-year revenue increase in Q2 2026, reaching USD 185.61 million, which surpassed analyst expectations. Despite narrowing its adjusted loss per share, the company remains in a loss-making phase. Analyst targets for Glaukos stock vary significantly, reflecting differing valuations based on the company's execution in glaucoma and corneal disorder products.
Form 4 Glaukos Corp For: 28 September By Investing.com
This article from Investing.com is a regulatory filing notification, specifically a Form 4 for Glaukos Corp, dated September 28. It indicates an insider transaction or change in beneficial ownership for the company. The content primarily serves as a placeholder for the filing and does not provide detailed financial analysis or specific transaction information.
Glaukos chief development officer sells $249k in stock By Investing.com
Glaukos' Chief Development Officer, Tomas Navratil, sold $249,158 worth of common stock on September 25, 2026, under a Rule 10b5-1 trading plan. Despite this insider sale, Glaukos shares have seen a 98% surge over the past year, though InvestingPro analysis suggests the stock is currently overvalued. The company recently reported strong Q2 2026 financial results, exceeding Wall Street expectations, leading several analysts to raise their price targets.
Glaukos (GKOS) officer sells shares under a preset plan at weighted-average prices from $151.70 to $154.88
Tomas Navratil, Chief Development Officer at Glaukos Corp (GKOS), sold a total of 1,615 common shares on September 25, 2026, through four separate transactions. These sales were executed under a Rule 10b5-1 trading plan adopted on June 12, 2026, with weighted-average prices ranging from $151.70 to $154.88 per share. After these transactions, Navratil directly holds 70,818 common shares, which includes 38,817 restricted stock units that are not yet vested.
Glaukos options activity points to bullish call spread targeting $180
Options trading activity for Glaukos (GKOS) indicates a bullish call spread targeting $180 by October 16, 2026. This strategy involves buying $160 calls and selling $180 calls, suggesting an expectation of a significant rally from its current trading price of $159.01. The trade coincides with an increase in implied volatility and mixed technical signals, despite recent insider selling and a "Neutral" analyst rating.
Form 144 GLAUKOS Corp For: 26 September By Investing.com
This article is a brief announcement from Investing.com stating that Glaukos Corp (GKOS) has filed a Form 144 for September 26th. Form 144 filings indicate an intent to sell restricted securities. The article provides no further details beyond this announcement.
A Glaukos (NYSE: GKOS) officer proposes selling 1,615 shares on September 25.
An officer at Glaukos (NYSE: GKOS), Tomas Navratil, has proposed selling 1,615 common shares valued at approximately $249,157.98, with an anticipated sale date of September 25, 2026. These shares originated from restricted stock vesting on March 22, 2025. The filing also notes three previous sales by Navratil in July, August, and September of 2026.
Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
Glaukos Corporation has partnered with NBA champion Stephen Curry to launch the "Could it be KC?" campaign, aimed at raising awareness and promoting earlier detection of keratoconus (KC), a progressive eye disease. Curry, who lives with KC, will share his personal journey to educate the public and encourage proactive eye care. The campaign will provide resources for individuals and families, emphasizing early education and timely evaluation to address the underdiagnosis and undertreatment of KC, particularly in diverse and underserved communities.
$1000 Invested In Glaukos 10 Years Ago Would Be Worth This Much Today
Glaukos (NYSE: GKOS) has shown strong performance over the last decade, outperforming the market with an average annual return of 14.97%. An investment of $1000 in Glaukos 10 years ago would now be valued at $4,143.70, highlighting the significant impact of compounded returns. The company currently holds a market capitalization of $9.57 billion.
The Technical Signals Behind (GKOS) That Institutions Follow
Glaukos Corporation (NASDAQ: GKOS) is showing weak near and mid-term sentiment despite a positive long-term outlook. AI models have generated distinct trading strategies, including a position trading strategy, a momentum breakout strategy, and a risk hedging strategy, to help optimize position sizing and manage drawdown risk. The analysis highlights a 43.5:1 risk-reward short setup targeting a 12.6% downside against a 0.3% risk.
Glaukos stock holds near yearly highs as insider sale draws attention
Glaukos Corporation (GKOS) stock is trading near its 52-week high after a significant 44.78% year-to-date gain as of September 17, 2026. An insider sale by Chief Development Officer Tomas Navratil on September 16, 2026, involving 1,457 shares at prices between USD 163.20 and USD 172.00, highlights the stock's strong performance. Glaukos, a mid-cap ophthalmic company, had a market capitalization of approximately USD 5.495 billion on September 17, 2026.
Glaukos chief development officer Tomas Navratil sells $243k in shares
Tomas Navratil, Glaukos's Chief Development Officer, sold 1,457 shares of the company's stock for approximately $243,203 on September 16, 2026. This sale occurred while Glaukos stock has seen over 90% growth in the past year, though InvestingPro analysis suggests it is currently overvalued. The transaction was conducted under a Rule 10b5-1 trading plan adopted in June 2026.
Glaukos (NYSE: GKOS) officer lines up new stock sale after $2.48M August trade
Glaukos officer Tomas Navratil has filed a Rule 144 notice to sell 1,457 common shares stemming from restricted stock vesting in March 2025. This planned sale follows several prior open-market sales by Navratil, including a significant transaction on August 28, 2026, where he sold 13,744 shares for $2,483,097.96. The filing indicates these shares are tied to compensation and handled by Fidelity Brokerage Services LLC as attorney-in-fact.
Glaukos Corp (GKOS) Shares Fall 5.2% -- What GF Score of 77 Tells Investors
Glaukos Corp (GKOS) shares recently fell 5.2% to $170.38, despite a 94.7% annual increase year-to-date. The stock is considered overvalued by 12.4% according to GuruFocus's GF Value™ estimate of $151.61, and its high forward P/E ratio of 338.8x makes traditional valuation difficult. While it boasts strong growth potential and financial strength, its low profitability and significant insider selling, despite guru accumulation, suggest caution for investors.
Glaukos Corp (NYSE: GKOS) Share Price, GKOS Stock News, GKOS Share Price & Updates
This article provides a detailed overview of Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company. It includes key metrics, financial statements, peer comparisons, and an AI-generated summary highlighting its product offerings, long-term growth drivers, and associated risks. The company develops therapies for glaucoma, corneal disorders, and retinal diseases, with products like iStent and iDose TR.
Glaukos chief development officer sells $2.48m in shares By Investing.com
Tomas Navratil, Glaukos Corp's Chief Development Officer, sold approximately $2.48 million worth of company shares on August 28, 2026. This transaction involved 13,744 shares at prices ranging from $179.69 to $182.50. Despite the sale, Glaukos has seen an 88% return over the past year, and the company recently surpassed Q2 2026 revenue expectations, leading several analysts to raise their price targets.
Glaukos chief development officer sells $2.48m in shares By Investing.com
Tomas Navratil, Glaukos Corp's Chief Development Officer, sold approximately $2.48 million worth of company shares on August 28, 2026, comprising 13,744 shares at prices ranging from $179.69 to $182.50. Following these transactions, Navratil beneficially owns 73,890 shares. The sale occurred after a significant stock return, though InvestingPro analysis suggests the stock may be overvalued despite strong recent financial results and raised analyst price targets.
Glaukos chief development officer sells $2.48m in shares
Tomas Navratil, Glaukos's Chief Development Officer, sold approximately $2.48 million worth of company shares on August 28, 2026. This transaction involved 13,744 shares at prices ranging from $179.69 to $182.50. Despite the company's strong stock performance over the past year and positive analyst outlooks, InvestingPro analysis suggests the stock is currently overvalued.
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today
Glaukos (NYSE: GKOS) has significantly outperformed the market over the last five years, with an annualized return of 26.17%. A $100 investment in Glaukos five years ago would now be worth $321.19, demonstrating the power of compounded returns. The company currently has a market capitalization of $10.97 billion.
Glaukos (GKOS) Stock Looks Pricey On High Growth Expectations
Glaukos (GKOS) stock has seen significant gains over the past five years, but its current valuation, particularly its high P/S ratio of 18.2x compared to an industry average of 3.0x, suggests it is expensive. The article notes that the stock's price reflects high expectations for future growth in ophthalmology treatments, indicating limited margin for error if these growth targets are not met. While some investors see strong product adoption, others are concerned about potential downward pressure on healthcare reimbursement.
Glaukos director Kliman sells $475,000 in shares
Glaukos director Gilbert H. Kliman recently sold 2,500 shares of common stock for $475,000, while also acquiring 2,500 shares through stock option exercise for $64,425. These transactions occurred as GLAUKOS stock is near its 52-week high, having returned 106% over the past year. The company also reported strong Q2 2026 financial results, surpassing expectations and leading to increased price targets from several analysts.
Glaukos (NYSE: GKOS) director sells shares after option exercise
Glaukos director Gilbert H. Kliman exercised stock options for 2,500 shares at $25.77 each and subsequently sold all 2,500 shares at $190.00 per share on August 19, 2026. After these transactions, Kliman retains stock options for 12,500 shares and holds 2,501 restricted stock units. The sale generated approximately $475,000 in gross proceeds, with a pre-tax spread of about $411,000.
GKOS Stock Surges 67% Year to Date: What's Driving the Rally?
Glaukos (GKOS) shares have surged 67.9% year to date, significantly outperforming its industry, driven by strong operating momentum and the commercial success of iDose TR and Epioxa. The company has raised its 2026 revenue guidance, reflecting its transition into a broader ophthalmology platform with a diverse pipeline. While facing competition and reimbursement risks, GKOS's exceptional growth is attributed to its innovative product launches and international expansion.
GKOS Stock Surges 67% Year to Date: What's Driving the Rally?
Glaukos (GKOS) stock has surged 67% year-to-date, significantly outperforming its industry, driven by strong adoption of iDose TR and the successful launch of Epioxa. The company's revenue jumped 49.5% in Q2, leading to an increased 2026 revenue guidance. While the company is expanding its ophthalmology platform and pipeline, investors should consider execution risks related to reimbursement, competition, and new product launches despite the positive growth outlook.
Glaukos Corp stock hits all-time high at 190.27 USD
Glaukos Corp's stock has reached an all-time high of $190.27, following a 111.6% increase over the past year and a significant revenue growth of 41.55% in the last twelve months. This surge is attributed to strong Q2 2026 financial results, which surpassed Wall Street expectations, leading to upward revisions in price targets from several analyst firms. Despite its strong performance, InvestingPro analysis suggests the stock is currently overvalued.
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
Glaukos (GKOS) reported a smaller-than-expected Q2 loss of $0.14 per share, surpassing the Zacks Consensus Estimate of a $0.28 loss. The company also exceeded revenue expectations, posting $185.61 million against a consensus of $149.57 million. Despite outperforming the market year-to-date, the stock currently holds a Zacks Rank #4 (Sell) due to unfavorable estimate revisions.
Glaukos (NYSE:GKOS) Reaches New 12-Month High - Should You Buy?
Glaukos (NYSE:GKOS) recently hit a new 52-week high of $190.06, reaching an $11.19 billion market capitalization. Despite a "Moderate Buy" consensus from analysts, their average price target of $177.33 is below the current share price. The company reported better-than-expected quarterly results, with revenue up 49.6% year-over-year, although insiders have sold approximately $19.1 million in stock over the last three months.
Glaukos (NYSE: GKOS) holder to sell 2,500 shares in 2026
A Glaukos (NYSE: GKOS) shareholder, Gilbert H. Kliman, plans to sell 2,500 shares of common stock on or after August 19, 2026, through Fidelity Brokerage Services LLC on the NYSE. The aggregate market value of these shares is $475,000, and the sale is associated with a stock option exercise. This information was disclosed in a Form 144 SEC filing, which outlines conditions for reselling restricted or insider-held shares.
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos Corporation (GKOS) is identified as a stock to retain due to strong growth prospects from its iDose TR and Epioxa franchises, leading to an increased sales outlook and margin expansion. Despite potential challenges like Medicare coverage uncertainty for iDose and temporary revenue volatility for Epioxa, the company's diversified pipeline across various ophthalmic therapeutic platforms supports long-term growth. Glaukos has demonstrated strong financial performance, with significant earnings surprises and positive stock performance year-to-date.
145,202 Shares in Glaukos Corporation $GKOS Bought by TimesSquare Capital Management LLC
TimesSquare Capital Management LLC has acquired 145,202 shares of Glaukos Corporation (NYSE:GKOS) worth approximately $20.3 million, representing a 0.25% stake in the medical instruments supplier. This comes as Glaukos reported strong quarterly revenue growth of 49.6% year over year, reaching $185.6 million, and institutional investors collectively own 99.04% of the company's stock. Despite significant insider selling totaling $19.1 million over the past three months, analysts maintain a "Moderate Buy" rating with a consensus price target of $177.33.
Glaukos Market Cap More Than Doubles in a Year to $11B
Glaukos Corp.'s market capitalization has surged to over $11 billion, more than double its value from a year ago, driven by investor confidence in its expansion beyond glaucoma into new areas of eye care. The Aliso Viejo-based company reported record second-quarter net sales of $185.6 million, a 50% year-over-year increase, and raised its full-year guidance. This growth is supported by the success of its iDose TR glaucoma implant and new therapies like Epioxa for keratoconus, along with ventures into treatments for Demodex blepharitis.
Oppenheimer Asset Management Inc. Invests $2.73 Million in Glaukos Corporation $GKOS
Oppenheimer Asset Management Inc. recently acquired a new stake of 19,564 shares in Glaukos Corporation, valued at approximately $2.73 million, during the second quarter. This move comes as institutional investors collectively own 99.04% of Glaukos, a medical instruments supplier that recently reported better-than-expected quarterly results with significant revenue growth. Despite strong institutional interest and positive analyst ratings, insiders have sold a considerable amount of stock, totaling $19.1 million over the past three months.
3 Stocks That May Be Trading Below Their Estimated Value By Up To 50%
This article identifies three US stocks—Datadog (DDOG), Super Micro Computer (SMCI), and Glaukos (GKOS)—that appear to be trading significantly below their estimated fair value based on future cash flow analyses. Despite market resilience and projected earnings growth, these companies show potential for investors seeking discounted opportunities, with Glaukos estimated to be undervalued by as much as 50%. The report provides an overview of each company's operations, financial performance, and estimated discount, while acknowledging potential risks like insider selling or legal challenges.
Walleye Capital LLC Takes $3.75 Million Position in Glaukos Corporation $GKOS
Walleye Capital LLC has acquired a new stake of $3.75 million in Glaukos Corporation (NYSE:GKOS) during the second quarter, making it one of many institutional investors holding 99.04% of the company's stock. Glaukos reported better-than-expected quarterly results with significant revenue growth, and analysts maintain a "Moderate Buy" rating despite recent insider share sales totaling over $19.1 million. The company is a medical technology firm focusing on micro-invasive glaucoma surgery (MIGS) and sustained drug-delivery solutions for eye diseases.
Glaukos President, COO Joseph E. Gilliam disposes of 60,000 shares worth $10.82 million
Joseph E. Gilliam, President and COO of Glaukos, sold 60,000 shares of common stock on August 11, 2026, for approximately $10.82 million. The shares were sold at weighted average prices of $178.89 and $180.49, after Gilliam exercised options for the same number of shares at lower prices. Following the transaction, his stake in Glaukos common stock was reduced to 72,588 shares.
Glaukos Insider Sold Shares Worth $10,784,659, According to a Recent SEC Filing
An insider at Glaukos Corporation (GKOS) recently sold shares valued at $10,784,659, as reported in a recent SEC filing. This transaction comes amidst various analyst target price adjustments and the company's Q2 2026 earnings release, which showed narrower adjusted losses and increased revenue. Glaukos, an ophthalmic pharmaceutical and medical technology company, specializes in treatments for glaucoma, corneal disorders, and retinal diseases.
Insider Selling: Glaukos (NYSE:GKOS) COO Sells 60,000 Shares of Stock
Glaukos Corporation's COO, Joseph Gilliam, sold 60,000 shares of company stock for approximately $10.8 million, reducing his direct ownership by 45.25%. The sale occurred while Glaukos shares were trading near a 52-week high, and the company recently reported strong quarterly revenue and beat EPS estimates. Despite the insider selling, analyst sentiment remains largely positive, with a "Moderate Buy" consensus and several raised price targets.
Glaukos COO Joseph Gilliam sells $10.7m in stock
Glaukos Corporation's COO, Joseph Gilliam, sold 60,000 shares of company stock for $10.7 million after exercising stock options. These sales occurred when the stock was near its 52-week high, and Gilliam now beneficially owns 72,588 shares. The transactions follow recent strong Q2 2026 financial results for Glaukos, which led to increased price targets from several analyst firms.
Glaukos (GKOS) Is Up 6.7% After Raising 2026 Sales Guidance And Narrowing Quarterly Loss
Glaukos Corporation (GKOS) stock increased by 6.7% after the company reported narrowing quarterly losses and raised its 2026 net sales guidance to between US$680 million and US$700 million. This improved outlook, partly driven by a new CMS J code for Epioxa, reinforces confidence in revenue growth for its glaucoma and corneal therapies, though the company remains loss-making. Analysts project Glaukos to reach $1.1 billion in revenue and $113.0 million in earnings by 2029.
Glaukos (GKOS) Is Up 6.7% After Raising 2026 Sales Guidance And Narrowing Quarterly Loss
Glaukos (GKOS) shares rose 6.7% after the company increased its 2026 net sales guidance to US$680 million to US$700 million and narrowed its quarterly loss per share to US$0.31. This positive adjustment follows strong Q2 2026 sales of US$185.61 million and the introduction of a new CMS J code for its Epioxa therapies, which is expected to simplify billing and reimbursement. Despite the improved revenue outlook, the article highlights the ongoing challenge of the company being loss-making and reliant on supportive reimbursement policies.
Glaukos Corp stock hits all-time high at 184.45 USD
Glaukos Corp (GKOS) stock has reached an all-time high of $184.45, reflecting a 100.01% increase over the past year and a 41.55% revenue surge in Q2 2026. Despite an InvestingPro analysis suggesting the stock may be overvalued, 11 analysts have revised earnings upwards, indicating continued optimism. The company also reported strong Q2 2026 financial results, exceeding analyst expectations and leading several firms to raise their price targets.
Glaukos SVP & CFO Alex Thurman sells $3.6m in GKOS stock
Alex R. Thurman, SVP and CFO of Glaukos Corp, sold 20,000 shares of GKOS stock for approximately $3.6 million, while also exercising stock options for 20,000 shares. These transactions were performed under a Rule 10b5-1 trading plan. The sale comes as Glaukos stock trades near its 52-week high, and the company recently reported strong Q2 2026 results, leading to multiple analyst price target increases.
Glaukos (GKOS) Is Up 6.7% After Raising 2026 Sales Guidance And Narrowing Quarterly Loss
Glaukos (GKOS) reported strong second-quarter 2026 results, with sales increasing to US$185.61 million and a narrowed basic loss per share. The company raised its full-year 2026 net sales guidance to US$680 million to US$700 million, reflecting increased confidence in its revenue outlook. A new CMS J code for Epioxa and Epioxa HD is expected to support the uptake of its newer therapies, though reimbursement and pricing pressures remain key risks.
Insider Selling: Glaukos (NYSE:GKOS) CFO Sells 20,000 Shares of Stock
Glaukos CFO Alex Thurman sold 20,000 shares of GKOS stock for $3.6 million on August 7th, reducing his direct holdings by 31.3%. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, Glaukos stock recently traded up 0.9% to $182.97, near its 52-week high, following strong quarterly results that beat analyst expectations.
GLAUKOS Corp SEC Filing (Aug 11, 2026)
GLAUKOS Corp (GKOS) filed a Form 144 with the SEC on August 11, 2026, indicating a proposed sale of 60,000 shares of common stock acquired through a stock option exercise on the same date. The aggregate market value of these shares is $10,784,645.13, and they are to be sold via Fidelity Brokerage Services LLC on the NYSE. The filing represents a neutral impact and sentiment according to AI-generated analysis.
Assenagon Asset Management S.A. Has $15.20 Million Stock Position in Glaukos Corporation $GKOS
Assenagon Asset Management S.A. significantly increased its stake in Glaukos Corporation (NYSE:GKOS) by 932.5% in the second quarter, now holding 108,736 shares valued at approximately $15.2 million. Glaukos reported strong Q2 earnings with a 49.6% revenue increase year-over-year and beat analyst EPS expectations, though company insiders sold $5.44 million worth of stock in the last 90 days. Analysts maintain a "Moderate Buy" rating for GKOS, with an average price target of $177.33.
How (GKOS) Movements Inform Risk Allocation Models
This article analyzes Glaukos Corporation (NASDAQ: GKOS) using AI models, identifying strong sentiment across all horizons and suggesting an overweight bias. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels for different risk profiles. The analysis also provides multi-timeframe signal strengths, support, and resistance levels.
Glaukos (GKOS) Q2 2026 Earnings Call Transcript
Glaukos (GKOS) reported record second-quarter 2026 net sales of $185.6 million, a 50% increase year-over-year, driven by strong adoption of iDose TR and the launch of Epioxa. The company raised its full-year 2026 net sales guidance to $680 million to $700 million and provided updated guidance for its various segments, including a 20% growth target for Corneal Health and 50% for U.S. Glaucoma. Management highlighted ongoing investments in its pipeline and commercial infrastructure, maintaining a focus on disciplined capital allocation despite anticipated near-term volatility in the Corneal Health segment due to J-code transitions.
